KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Other Non-Current Assets: 2011-2024

Historic Other Non-Current Assets for Supernus Pharmaceuticals (SUPN) over the last 14 years, with Dec 2024 value amounting to $31.5 million.

  • Supernus Pharmaceuticals' Other Non-Current Assets was N/A to $62.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $62.4 million, marking a year-over-year change of. This contributed to the annual value of $31.5 million for FY2024, which is 15.94% down from last year.
  • As of FY2024, Supernus Pharmaceuticals' Other Non-Current Assets stood at $31.5 million, which was down 15.94% from $37.5 million recorded in FY2023.
  • Supernus Pharmaceuticals' Other Non-Current Assets' 5-year high stood at $49.2 million during FY2021, with a 5-year trough of $31.5 million in FY2024.
  • In the last 3 years, Supernus Pharmaceuticals' Other Non-Current Assets had a median value of $37.5 million in 2023 and averaged $36.3 million.
  • Per our database at Business Quant, Supernus Pharmaceuticals' Other Non-Current Assets surged by 97.54% in 2020 and then dropped by 19.15% in 2022.
  • Yearly analysis of 5 years shows Supernus Pharmaceuticals' Other Non-Current Assets stood at $43.2 million in 2020, then increased by 13.83% to $49.2 million in 2021, then decreased by 19.15% to $39.8 million in 2022, then dropped by 5.78% to $37.5 million in 2023, then fell by 15.94% to $31.5 million in 2024.